Navigation Links
Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC
Date:1/23/2012

WHAT: The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation (CRF) is a comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on preclinical and clinical studies on the path to commercialization, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.

Noteworthy presentations include a potential role for cell therapy in metabolic syndrome, large-scale studies in patients with heart failure and ST segment elevation myocardial infarction (STEMI) and early phase studies with new biologics involving endometrial cells.

Conference Highlights Include:

  • Periadventitial MAPC Administration in STEMI: Results and Phase II Study
    Thursday, January 26, 2012; 9:00 AM

    Drs. Marc Penn and Warren Sherman will present 1-year results of a Phase 1 clinical trial involving an allogeneic bone marrowderived adherent adult stem cell product in patients with first ST-elevationmyocardial infarction (STEMI). Preliminary 4-month results were recently published in the journal, Circulation Research: http://circres.ahajournals.org/content/110/2/304.full. Investigators will also describe the Phase 2 trial scheduled to begin later this year.

  • SCIPIO: Autologous Cardiac-Derived Stem Cells for LV Dysfunction
    Thursday, January 26, 2012; 1:10 PM

    Dr. Roberto Bolli will present new data on cardiac MRI analyses, as well as, surgical feasibility and safety data from the SCIPIO trial. SCIPIO is a first-in-human, Phase 1, randomized trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with ischemic cardiomyopathy and heart failure. Initial results published in The Lancet showed that intracoronary infusion of autologous CSCs results in a striking improvement in left ventricular ejection fraction, NYHA functional class, quality of life, and in a significant reduction in infarct size.

  • CD34+ Cells for Refractory Angina: ACT 34 CMI Update and Phase 3 Study Design
    Thursday, January 26, 2012; 10:45 AM

    Dr. Timothy Henry will discuss results of the ACT 34 trial, the largest randomized, placebo-controlled, double-blind trial of CD34+ cell therapy for the treatment of patients with class III/IV refractory angina. Dr. Henry will also discuss the study design of a planned Phase III trial set to begin in 2012.

  • SDF-1 for Heart Failure: Results of a Phase I Trial
    Thursday, January 26, 2012; 1:30 PM

    Dr. Marc Penn will present 1-year clinical data results of a plasmid encoding human SDF-1 protein in patients with chronic heart failure. SDF-1 has been identified as a key regulator of stem cell trafficking to sites of cardiac injury and could potentially be used to treat chronic heart failure. Investigators initially found that after four months, patients exhibited clinically significant improvements in quality of life, six-minute walk distance, decreased heart failure symptoms and stabilization of myocardial function.

The latest conference agenda is available at http://celltherapy.crf.org/conference/agenda.html.

WHY: Now in its 11th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

In addition, Friday's sessions will focus on developing a rational policy towards stem cell study and utilization. Leading experts will also explore the benefits and drawbacks of stem cell tourism.

WHO:
Course Director
Warren Sherman, MD
New York-Presbyterian Hospital/Columbia University Medical Center
New York, NY

Course Co-Directors
Josef Bartunek, MD, PhD
Cardiovascular Center, OLV Hospital
Aalst, Belgium

Henricus J. Duckers, MD, PhD
Erasmus University Hospital
Rotterdam, Netherlands

Amit Patel, MD, MS
University of Utah
Salt Lake City, Utah

Marc S. Penn, MD, PhD
Summa Health System
Cleveland, Ohio

WHEN: January 25-27, 2012

WHERE: Vivian and Seymour Milstein Family Heart Center
Myrna L. Daniels Auditorium
NYPH/Columbia University Medical Center
173 Fort Washington Avenue, 1st Floor
New York, NY 10032

For more information visit: http://celltherapy.crf.org/

HOW TO REGISTER: Media may apply for registration by visiting http://celltherapy.crf.org/register/press-registration.html.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. International Diabetes Federation awards $2 million to 9 global diabetes research projects
3. Virtual Global Highlights Top Ten Misconceptions about Cloud Computing
4. Global Health Defined as Public Health in a New Lancet Commentary by the Association of Schools of Public Health (ASPH)
5. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
6. Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights
7. Now Serving 9 Billion: A Global Town Hall
8. The Global Leaders' Inaugural Meeting a Resounding Success
9. Language Service Leader Expands to Meet Booming, Global Industry Demand.
10. GenomeQuest Hosts Seminar Focused On Web-based Searching for Patent Information Across Global Sequence Databases
11. Global Nutrition Firm Takes Dose of SonicWALL to Boost Network Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... 2017 , ... Today, True Vision Funding LLC (TVF), a ... a new division for the purchase of sports and music entertainment contracts, including ... Clinton Portis, former Washington Redskins running back and supporter for TVF echoed his ...
(Date:3/1/2017)... ... March 01, 2017 , ... After a long period of indulging in ... juice cleanses and workouts top the detox categories, there is a rare yet successful ... Kerry Gaynor Method’s Vital Lung Detox is an herbal-based formula designed to help cleanse ...
(Date:3/1/2017)... ... March 01, 2017 , ... Look for a new collection of edible ... Drift Roses. Star Roses and Plants is launching their new Bushel and Berry ... and Berry Collection makes growing fresh fruit simple with a variety of easy-to-grow, low-maintenance ...
(Date:3/1/2017)... ... March 01, 2017 , ... Breast Surgeon, Dr. Dennis Holmes of ... stage breast cancer and where it fits in the treatment paradigm at Susan G. ... .” The event brings together leading cancer and wellness experts to share the latest ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite Peaks ... cancer screening rates by supporting the 80% by 2018 initiative, led by the ... the National Colorectal Cancer Roundtable (an organization co-founded by ACS and CDC). , ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... DIEGO , March 1, 2017  Aethlon ... European Patent Office has granted European Patent Number ... In recent years, exosomes have emerged ... a wide range of disease conditions, including cancer, ... (CTE).  This granted European Patent is an important ...
(Date:3/1/2017)... 1, 2017  Numotion, the nation,s leading provider of ... Tek RMD ("robotic mobilization device") by Matia Robotics in ... is a motorized standing movement device that offers the ... to complete everyday activities from a standing position. Unlike ... RMD unassisted. Numotion is the exclusive distributor of the ...
(Date:3/1/2017)... ... and Markets has announced the addition of the "Global Infertility ... The Global Infertility Therapy Partnering Terms and Agreements since 2010 ... into by the world,s leading healthcare companies. The report ... discovery or development stage whereby the licensee obtains a right or ...
Breaking Medicine Technology: